microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest

RNA Biology

Volumn 12, Issue 5, 2015, Pages 538-554

  Zhao, Zhenze ^a   Ma, Xiuye ^a   Sung, Derek ^a   Li, Monica ^a   Kosti, Adam ^a   Lin, Gregory ^a   Chen, Yidong ^a   Pertsemlidis, Alexander ^a   Hsiao, Tzu Hung ^b   Du, Liqin ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cell cycle arrest; Differentiation; Differentiation therapy; MicroRNA; Neuroblastoma

Indexed keywords

BETA TUBULIN; CYCLIN DEPENDENT KINASE 6; LYMPHOID ENHANCER FACTOR 1; MESSENGER RNA; MICROFIBRIL ASSOCIATED PROTEIN 4; MICRORNA; MICRORNA 449A; NEUROMODULIN; NEURON SPECIFIC ENOLASE; PLAKOPHILIN 4; TRANSFER RNA SPLICING ENDONUCLEASE 15 HOMOLOG PROTEIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CDK6 PROTEIN, HUMAN; LEF1 PROTEIN, HUMAN; MIRN449 MICRORNA, HUMAN; TUMOR PROTEIN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE TARGETING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NERVE FIBER GROWTH; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; BIOLOGICAL MODEL; CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; REPRODUCIBILITY; SURVIVAL ANALYSIS;

3' UNTRANSLATED REGIONS; APOPTOSIS; BASE SEQUENCE; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 6; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MICRORNAS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEUROBLASTOMA; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 84930521497     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.1080/15476286.2015.1023495     Document Type: Article

References (74)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369(9579): 2106-20; PMID: 17586306
2. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24(1): 65-86; PMID: 20113896; http: //dx. doi. org/10. 1016/j. hoc. 2009. 11. 011
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3(3): 203-16; PMID: 12612655; http: //dx. doi. org/10. 1038/nrc1014
4. Reynolds CP. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr Oncol Rep 2000; 2(6): 511-8; PMID: 11122886; http: //dx. doi. org/ 10. 1007/s11912-000-0104-y
5. Cruz FD, Matushansky I. Solid tumor differentiation therapy-is it possible? Oncotarget 2012; 3(5): 559-67; PMID: 22643847
6. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood 2009; 113(16): 3655-65; PMID: 19221035; http: //dx. doi. org/10. 1182/blood-2009-01-198911
7. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009; 27(7): 1007-13; PMID: 19171716; http: //dx. doi. org/10. 1200/JCO. 2007. 13. 8925
8. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. Children's Cancer Group. N Engl J Med 1999; 341(16): 1165-73; PMID: 10519894; http: //dx. doi. org/10. 1056/NEJM199910143411601
9. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009; 28(3-4): 369-78; PMID: 20012925; http: // dx. doi. org/10. 1007/s10555-009-9188-5
10. Li M, Li J, Ding X, He M, Cheng SY. microRNA and cancer. Aaps J 2010; 12(3): 309-17; PMID: 20422339; http: //dx. doi. org/10. 1208/s12248-010-9194-0
11. Kinoshita T, Hanazawa T, Nohata N, Kikkawa N, Enokida H, Yoshino H, Yamasaki T, Hidaka H, Nakagawa M, Okamoto Y, et al. Tumor suppressive micro-RNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget 2012; 3(11): 1386-400; PMID: 23159910
12. Kopp F WE, Roidl A. The proto-oncogene KRAS is targeted by miR-200c. Oncotarget 2013; 5: 185-95; PMID: 24368337
13. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, Xiang C, Poisson L, de Carvalho AC, Slavin S, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 2013; 4(5): 665-76; PMID: 23714687
14. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther: J Am Soc Gene Ther 2011; 19(6): 1116-22; PMID: 21427705; http: //dx. doi. org/10. 1038/mt. 2011. 48
15. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137(6): 1005-17; PMID: 19524505; http: //dx. doi. org/10. 1016/j. cell. 2009. 04. 021
16. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438 (7068): 685-9; PMID: 16258535; http: //dx. doi. org/ 10. 1038/nature04303
17. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011; 19(6): 1116-22; PMID: 21427705; http: //dx. doi. org/10. 1038/mt. 2011. 48
18. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010; 70 (18): 7027-30; PMID: 20807816; http: //dx. doi. org/ 10. 1158/0008-5472. CAN-10-2010
19. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 2009; 119 (8): 2119-23; PMID: 19620782
20. Zhao Z, Ma X, Hsiao TH, Lin G, Kosti A, Yu X, Suresh U, Chen Y, Tomlinson GE, Pertsemlidis A, et al. A high-content morphological screen identifies novel microRNAs that regulate neuroblastoma cell differentiation. Oncotarget 2014; 5(9): 2499-512; PMID: 24811707
21. Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell 2007; 27(3): 435-48; PMID: 17679093; http: //dx. doi. org/10. 1016/j. molcel. 2007. 07. 015
22. Annibali D, Gioia U, Savino M, Laneve P, Caffarelli E, Nasi S. A new module in neural differentiation control: two microRNAs upregulated by retinoic acid, miR-9 and-103, target the differentiation inhibitor ID2. PLoS One 2012; 7(7): e40269; PMID: 22848373; http: //dx. doi. org/10. 1371/journal. pone. 0040269
23. Le MT, Xie H, Zhou B, Chia PH, Rizk P, Um M, Udolph G, Yang H, Lim B, Lodish HF. MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol 2009; 29 (19): 5290-305; PMID: 19635812; http: //dx. doi. org/ 10. 1128/MCB. 01694-08
24. Foley NH, Bray I, Watters KM, Das S, Bryan K, Bernas T, Prehn JH, Stallings RL. MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ 2011; 18(7): 1089-98; PMID: 21212796; http: //dx. doi. org/10. 1038/ cdd. 2010. 172
25. Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 2010; 16 (10): 1134-40; PMID: 20871609; http: //dx. doi. org/ 10. 1038/nm. 2227
26. Martin A, Jones A, Bryar PJ, Mets M, Weinstein J, Zhang G, Laurie NA. MicroRNAs-449a and-449b exhibit tumor suppressive effects in retinoblastoma. Biochem Biophys Res Commun 2013; 440(4): 599-603; PMID: 24120948; http: //dx. doi. org/10. 1016/j. bbrc. 2013. 09. 117
27. Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q, Qiu X, Wang E. MicroRNA-449a is downregulated in nonsmall cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One 2013; 8(5): e64759; PMID: 23734217; http: //dx. doi. org/10. 1371/journal. pone. 0064759
28. Noonan EJ, Place RF, Basak S, Pookot D, Li LC. miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget 2010; 1 (5): 349-58; PMID: 20948989
29. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009; 28(14): 1714-24; PMID: 19252524; http: //dx. doi. org/10. 1038/onc. 2009. 19
30. Lize M, Pilarski S, Dobbelstein M. E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ 2010; 17 (3): 452-8; PMID: 19960022; http: //dx. doi. org/ 10. 1038/cdd. 2009. 188
31. Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, Yu Q. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev 2009; 23(20): 2388-93; PMID: 19833767; http: //dx. doi. org/10. 1101/gad. 1819009
32. Wei B, Song Y, Zhang Y, Hu M. microRNA-449a functions as a tumor-suppressor in gastric adenocarcinoma by targeting Bcl-2. Oncol Lett 2013; 6(6): 1713-8; PMID: 24260067
33. Chen S, Dai Y, Zhang X, Jin D, Li X, Zhang Y. Increased miR-449a expression in colorectal carcinoma tissues is inversely correlated with serum carcinoembryonic antigen. Oncol Lett 2014; 7(2): 568-72; PMID: 24396489
34. Buechner J, Tomte E, Haug BH, Henriksen JR, Lokke C, Flaegstad T, Einvik C. Tumour-suppressor micro-RNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 2011; 105(2): 296-303; PMID: 21654684; http: //dx. doi. org/10. 1038/ bjc. 2011. 220
35. Radio NM, Breier JM, Shafer TJ, Mundy WR. Assessment of chemical effects on neurite outgrowth in PC12 cells using high content screening. Toxicol Sci 2008; 105(1): 106-18; PMID: 18539913; http: //dx. doi. org/ 10. 1093/toxsci/kfn114
36. Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, So KF, Chang RC. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 2009; 30 (1): 127-35; PMID: 19056420; http: //dx. doi. org/ 10. 1016/j. neuro. 2008. 11. 001
37. Mao L, Ding J, Zha Y, Yang L, McCarthy BA, King W, Cui H, Ding HF. HOXC9 links cell-cycle exit and neuronal differentiation and is a prognostic marker in neuroblastoma. Cancer Res 2011; 71(12): 4314-24; PMID: 21507931; http: //dx. doi. org/10. 1158/0008-5472. CAN-11-0051
38. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A 2006; 103(11): 4034-9; PMID: 16495412; http: //dx. doi. org/10. 1073/pnas. 0510928103
39. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466(7308): 835-40; PMID: 20703300; http: //dx. doi. org/10. 1038/ nature09267
40. Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, Wistuba, II, Ji L, Roth JA, Minna JD, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res: MCR 2009; 7(8): 1234-43; PMID: 19671678; http: //dx. doi. org/10. 1158/1541-7786. MCR-08-0507
41. Du L, Subauste MC, DeSevo C, Zhao Z, Baker M, Borkowski R, Schageman JJ, Greer R, Yang CR, Suraokar M, et al. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One 2012; 7(6): e39167; PMID: 22723956; http: //dx. doi. org/10. 1371/journal. pone. 0039167
42. Du L, Zhao Z, Ma X, Hsiao TH, Chen Y, Young E, Suraokar M, Wistuba I, Minna JD, Pertsemlidis A. miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene 2013; 33: 4307-15; PMID: 24037530; http: //dx. doi. org/10. 1038/onc. 2013. 381
43. Feliciano DM, Edelman AM. Repression of Ca2+/calmodulin-dependent protein kinase IV signaling accelerates retinoic acid-induced differentiation of human neuroblastoma cells. J Biol Chem 2009; 284 (39): 26466-81; PMID: 19633294; http: //dx. doi. org/ 10. 1074/1074. M109. 027680
44. Krek A, Grun D, PoyMN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37(5): 495-500; PMID: 15806104; http: //dx. doi. org/10. 1038/10381536
45. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007; 282(19): 14328-36; PMID: 17363372; http: //dx. doi. org/10. 1074/1074. M611393200
46. Lal A, Thomas MP, Altschuler G, Navarro F, O'Day E, Li XL, Concepcion C, Han YC, Thiery J, Rajani DK, et al. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet 2011; 7(11): e1002363; PMID: 22102825; http: //dx. doi. org/10. 1371/1371. pgen. 1002363
47. Kocak H, Ackermann S, Hero B, Kahlert Y, Oberthuer A, Juraeva D, Roels F, Theissen J, Westermann F, Deubzer H, et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis 2013; 4: e586; PMID: 23579273; http: //dx. doi. org/10. 1038/ 1038. 2013. 84
48. Oberthuer A, Juraeva D, Li L, Kahlert Y, Westermann F, Eils R, Berthold F, Shi L, Wolfinger RD, Fischer M, et al. Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. Pharmacogenomics J 2010; 10(4): 258-66; PMID: 20676065; http: //dx. doi. org/10. 1038/1038. 2010. 53
49. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136(2): 215-33; PMID: 19167326; http: //dx. doi. org/10. 1016/1016. cell. 2009. 01. 002
50. Leucht C, Stigloher C, Wizenmann A, Klafke R, Folchert A, Bally-Cuif L. MicroRNA-9 directs late organizer activity of the midbrain-hindbrain boundary. Nat Neurosci 2008; 11(6): 641-8; PMID: 18454145; http: // dx. doi. org/10. 1038/1038. 2115
51. Hudson RS, YiM, EspositoD, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, et al, MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 2012; 40(8): 3689-703; PMID: 22210864; http: //dx. doi. org/10. 1093/1093/gkr1222
52. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70(14): 5923-30; PMID: 20570894; http: //dx. doi. org/10. 1158/0008-5472. CAN-10-0655
53. Schlosser A, Thomsen T, Shipley JM, Hein PW, Brasch F, Tornoe I, Nielsen O, Skjodt K, Palaniyar N, Steinhilber W, et al. Microfibril-associated protein 4 binds to surfactant protein A (SP-A) and colocalizes with SP-A in the extracellular matrix of the lung. Scand J Immunol 2006; 64(2): 104-16; PMID: 16867155; http: //dx. doi. org/10. 1111/1111. 1365-3083. 2006. 01778. x
54. Kasamatsu S, Hachiya A, Fujimura T, Sriwiriyanont P, Haketa K, Visscher MO, Kitzmiller WJ, Bello A, Kitahara T, Kobinger GP, et al. Essential role of microfibrillar-associated protein 4 in human cutaneous homeostasis and in its photoprotection. Sci Rep 2011; 1: 164; PMID: 22355679; http: //dx. doi. org/10. 1038/ 103800164
55. Keil R, Schulz J, Hatzfeld M. p0071/00714, a multifunctional protein coordinating cell adhesion with cytoskeletal organization. Biol Chem 2013; 394(8): 1005-17; PMID: 23640939; http: //dx. doi. org/10. 1515/ 1515-2013-0114
56. Wolf A, Keil R, Gotzl O, Mun A, Schwarze K, Lederer M, Huttelmaier S, Hatzfeld M. The armadillo protein p0071 regulates Rho signalling during cytokinesis. Nat Cell Biol 2006; 8(12): 1432-40; PMID: 17115030; http: //dx. doi. org/10. 1038/10381504
57. Dhungel N, Hopper AK. Beyond tRNA cleavage: novel essential function for yeast tRNA splicing endonuclease unrelated to tRNA processing. Genes Dev 2012; 26 (5): 503-14; PMID: 22391451; http: //dx. doi. org/ 10. 1101/1101. 183004. 111
58. Bullrich F, MacLachlan TK, Sang N, Druck T, Veronese ML, Allen SL, Chiorazzi N, Koff A, Heubner K, Croce CM, et al. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res 1995; 55(6): 1199-205; PMID: 7882308
59. Lu X, Fang Y, Wang Z, Xie J, Zhan Q, Deng X, Chen H, Jin J, Peng C, Li H, et al. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Cell Tissue Res 2013; 354(3): 891-6; PMID: 24026436; http: //dx. doi. org/10. 1007/ 100700441-013-1711-x
60. Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, Wei J, Peng Y, Zou X, Pellicer A, et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res 2009; 69(8): 3332-8; PMID: 19351848; http: //dx. doi. org/10. 1158/0008-5472. CAN-08-3380
61. Wang WJ, Yao Y, Jiang LL, Hu TH, Ma JQ, Ruan ZP, Tian T, Guo H, Wang SH, Nan KJ. Increased LEF1 expression and decreased Notch2 expression are strong predictors of poor outcomes in colorectal cancer patients. Dis Markers 2013; 35(5): 395-405; PMID: 24223455; http: //dx. doi. org/10. 1155/2013/983981
62. de la Roche M, Ibrahim AE, Mieszczanek J, Bienz M. LEF1 and B9L shield beta-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors. Cancer Res 2014; 74(5): 1495-505; PMID: 24419084; http: //dx. doi. org/10. 1158/0008-5472. CAN-13-2682
63. Ogasawara T, Kawaguchi H, Jinno S, Hoshi K, Itaka K, Takato T, Nakamura K, Okayama H. Bone morphogenetic protein 2-induced osteoblast differentiation requires Smad-mediated down-regulation of Cdk6. Mol Cell Biol 2004; 24(15): 6560-8; PMID: 15254224; http: //dx. doi. org/10. 1128/1128. 24. 15. 6560-6568. 2004
64. Valdivia LE, Young RM, Hawkins TA, Stickney HL, Cavodeassi F, Schwarz Q, Pullin LM, Villegas R, Moro E, Argenton F, et al. Lef1-dependent Wnt/beta-catenin signalling drives the proliferative engine that maintains tissue homeostasis during lateral line development. Development 2011; 138(18): 3931-41; PMID: 21862557; http: //dx. doi. org/10. 1242/1242. 062695
65. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115(7): 787-98; PMID: 14697198; http: //dx. doi. org/10. 1016/10160092-8674(03)01018-3
66. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37(5): 495-500; PMID: 15806104; http: //dx. doi. org/10. 1038/ 10381536
67. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120(1): 15-20; PMID: 15652477; http: //dx. doi. org/10. 1016/1016. cell. 2004. 12. 035
68. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97; PMID: 14744438; http: //dx. doi. org/10. 1016/10160092-8674(04)00045-5
69. Helwak A, Kudla G, Dudnakova T, Tollervey D. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 2013; 153 (3): 654-65; PMID: 23622248; http: //dx. doi. org/ 10. 1016/1016. cell. 2013. 03. 043
70. Chi SW, Hannon GJ, Darnell RB. An alternative mode of microRNA target recognition. Nat Struct Mol Biol 2012; 19(3): 321-7; PMID: 22343717; http: //dx. doi. org/10. 1038/1038. 2230
71. Reczko M, Maragkakis M, Alexiou P, Grosse I, Hatzigeorgiou AG. Functional microRNA targets in protein coding sequences. Bioinformatics 2012; 28(6): 771-6; PMID: 22285563; http: //dx. doi. org/10. 1093/1093/ bts043
72. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M Jr, Jungkamp AC, Munschauer M, et al. Transcriptomewide identification of RNA-binding protein and micro-RNA target sites by PAR-CLIP. Cell 2010; 141 (1): 129-41; PMID: 20371350; http: //dx. doi. org/ 10. 1016/1016. cell. 2010. 03. 009
73. van den Heuvel S, Harlow E. Distinct roles for cyclindependent kinases in cell cycle control. Science 1993; 262(5142): 2050-4; PMID: 8266103; http: //dx. doi. org/ 10. 1126/1126. 8266103
74. Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, Wistuba, II, Ji L, Roth JA, Minna JD, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009; 7(8): 1234-43; PMID: 19671678; http: //dx. doi. org/10. 1158/1541-7786. MCR-08-0507